Evidence map›Paper›PMID 31090263›Full record

ArticleJournal of Zhejiang University. Science. B2019

Tumor immunology and immunotherapy: a journey I started from Hangzhou.

Gen-Sheng Feng

Abstract readAutobiographyHistorical Article
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Zhejiang University. Science. B, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Gen-Sheng FengDepartment of Pathology, School of Medicine; Molecular Biology Section, Division of Biological Sciences; Moores Cancer Center, University of California at San Diego, La Jolla, California 92093-0864, USA.

Funding

Dissection of Pten-regulated signals in hepatopathogenesisR01CA188506 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FENG, GEN-SHENG · 2015 to 2019
$1.9M
Molecular and Cellular Communications in Liver TumorigenesisR01CA176012 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FENG, GEN-SHENG · 2014 to 2019
$1.7M
Shp2 and Pten in Leukemia and AnemiaR01HL129763 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FENG, GEN-SHENG · 2015 to 2018
$1.6M
NCI NIH HHS R01 CA176012NCI NIH HHS R01 CA188506NHLBI NIH HHS R01 HL129763
6 · The paper itself

Abstract

This short article is dedicated to the 90th Anniversary of the School of Life Sciences at Zhejiang University, China. Immunotherapy of cancer is currently a hot topic in the biomedical field, and a re-search focus of my laboratory is on developing new and effective combinatorial immunotherapeutic strategies for liver cancer. Of note, my interest in immunotherapy of cancer stems from the training as an undergraduate student at Hangzhou University, China, almost 40 years ago.

Indexed as

AnimalsAntineoplastic AgentsChinaHistory, 20th CenturyHistory, 21st CenturyHumansImmunologic FactorsImmunotherapyLiverLiver NeoplasmsMiceOncogenesSignal TransductionSynaptophysinUnited StatesUniversitiesAntineoplastic AgentsImmunologic FactorsSynaptophysinSYP protein, humanImmunotherapy; Liver cancer; Tumor immunology; 90th Anniversary

Identifiers

PMID31090263
PMCPMC6568228

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.